<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35043357</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3478</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>43</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title>
          <ISOAbbreviation>Neurol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy.</ArticleTitle>
        <Pagination>
          <StartPage>3949</StartPage>
          <EndPage>3956</EndPage>
          <MedlinePgn>3949-3956</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-022-05897-0</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We investigated the efficacy of low-dose prednisolone (PSL) regimen in patients with generalized myasthenia gravis (MG) post-thymectomy and its correlation with long-term outcome.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">This is a 2-year observational study. The subjects were aged 16-75 years, a Myasthenia Gravis Foundation of America (MGFA) clinical classification of II to IV, generalized MG after thymectomy. We selected a low-dose (5 mg/day) initiation and slowly incrementing (10 mg every 4 weeks) PSL therapy regimen. We collected the clinical characteristics, treatment-related data, and 2-year clinical outcomes of MG patients, and analyzed the effect of various factors on the achievement of the treatment target.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-three generalized MG were recruited in our study. After 2 years of observation, 52 patients (82.5%) of generalized MG achieved treatment goal. Based on the maximum daily dose of PSL received, the MG patients were divided into 20 mg, 30 mg, and ≥ 40 mg groups. Subgroup analysis showed that the 20 mg group had the highest rate of achieving the treatment target (94.9%), followed by the 30 mg group (73.3%) and the lowest rate was among the ≥ 40 mg group (44.4%). Using a multivariate logistic regression analysis, we identified that the maximum daily dose of PSL 20 mg was the only positive, independent predictor of treatment goal achievement after 2 years.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Low-dose initiation, slowly incrementing PSL therapy is feasible for generalized MG patients after thymectomy. Early response to low-dose PSL therapy may predict better long-term outcomes.</AbstractText>
          <CopyrightInformation>© 2022. Fondazione Società Italiana di Neurologia.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-4456-5762</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, South China Hospital, Health Science Center, Shenzhen University, No.1 Fuxin Road, Longgang District, Shenzhen, 518116, China. 8631550@qq.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. 8631550@qq.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Li</LastName>
            <ForeName>Fujun</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0003-0365-6024</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of General Surgery, South China Hospital, Health Science Center, Shenzhen University, No.1 Fuxin Road, Longgang District, Shenzhen, 518116, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Hongwen</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Management Science and Engineering, School of Management, Harbin Institute of Technology, Harbin, Heilongjiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Hongmei</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Tian</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Rehabilitation, The Second Hospital of Harbin, Harbin, Heilongjiang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Xudong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Affiliated Hospital of Northwest University, Xi'an No.3 Hospital, Xi'an, Shaanxi, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Neurol Sci</MedlineTA>
        <NlmUniqueID>100959175</NlmUniqueID>
        <ISSNLinking>1590-1874</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9PHQ9Y1OLM</RegistryNumber>
          <NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="Y">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013934" MajorTopicYN="Y">Thymectomy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">Prednisolone</Keyword>
        <Keyword MajorTopicYN="N">Thymectomy</Keyword>
        <Keyword MajorTopicYN="N">Treatment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>7</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35043357</ArticleId>
        <ArticleId IdType="doi">10.1007/s10072-022-05897-0</ArticleId>
        <ArticleId IdType="pii">10.1007/s10072-022-05897-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gronseth GS, Barohn R, Narayanaswami P (2020) Practice advisory: thymectomy for myasthenia gravis (practice parameter update): report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 94:705–709. https://doi.org/10.1212/WNL.0000000000009294</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000009294</ArticleId>
            <ArticleId IdType="pubmed">32213645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe GI, Kaminski HJ, Aban IB et al (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375:511–522. https://doi.org/10.1056/NEJMoa1602489</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1602489</ArticleId>
            <ArticleId IdType="pubmed">27509100</ArticleId>
            <ArticleId IdType="pmc">5189669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolfe GI, Kaminski HJ, Aban IB et al (2019) Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol 18:259–268. https://doi.org/10.1016/S1474-4422(18)30392-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(18)30392-2</ArticleId>
            <ArticleId IdType="pubmed">30692052</ArticleId>
            <ArticleId IdType="pmc">6774753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475–490. https://doi.org/10.1016/S1474-4422(09)70063-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(09)70063-8</ArticleId>
            <ArticleId IdType="pubmed">19375665</ArticleId>
            <ArticleId IdType="pmc">2730933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis: executive summary. Neurology 87:419–425. https://doi.org/10.1212/WNL.0000000000002790</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002790</ArticleId>
            <ArticleId IdType="pubmed">27358333</ArticleId>
            <ArticleId IdType="pmc">4977114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai T, Utsugisawa K, Murai H et al (2018) Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. J Neurol Neurosurg Psychiatry 89:513–517. https://doi.org/10.1136/jnnp-2017-316625</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2017-316625</ArticleId>
            <ArticleId IdType="pubmed">29175893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16–23. https://doi.org/10.1212/wnl.55.1.16</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.55.1.16</ArticleId>
            <ArticleId IdType="pubmed">10891897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barohn RJ, McIntire D, Herbelin L et al (1998) Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 841:769–772. https://doi.org/10.1111/j.1749-6632.1998.tb11015.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1998.tb11015.x</ArticleId>
            <ArticleId IdType="pubmed">9668327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skeie GO, Apostolski S, Evoli A et al (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 17:893–902. https://doi.org/10.1111/j.1468-1331.2010.03019.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2010.03019.x</ArticleId>
            <ArticleId IdType="pubmed">20402760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murai H, Utsugisawa K, Nagane Y et al (2018) Rationale for the clinical guidelines for myasthenia gravis in Japan. Ann N Y Acad Sci 1413:35–40. https://doi.org/10.1111/nyas.13544</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.13544</ArticleId>
            <ArticleId IdType="pubmed">29377151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders DB, Evoli A (2010) Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43(5–6):428–435. https://doi.org/10.3109/08916930903518107</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08916930903518107</ArticleId>
            <ArticleId IdType="pubmed">20166870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE (2014) EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 21(5):687–693. https://doi.org/10.1111/ene.12359</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ene.12359</ArticleId>
            <ArticleId IdType="pubmed">24471489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H (2016) Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 263(8):1473–1494. https://doi.org/10.1007/s00415-016-8045-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-016-8045-z</ArticleId>
            <ArticleId IdType="pubmed">26886206</ArticleId>
            <ArticleId IdType="pmc">4971048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evoli A, Antonini G, Antozzi C, DiMuzio A, Habetswallner F, Iani C, Inghilleri M, Liguori R, Mantegazza R, Massa R, Pegoraro E, Ricciardi R, Rodolico C (2019) Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci 40(6):1111–1124. https://doi.org/10.1007/s10072-019-03746-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-019-03746-1</ArticleId>
            <ArticleId IdType="pubmed">30778878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group Neurology 50:1778–1783. https://doi.org/10.1212/wnl.50.6.1778</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.50.6.1778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilhus NE, Skeie GO, Romi F et al (2016) Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12:259–268. https://doi.org/10.1038/nrneurol.2016.44</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2016.44</ArticleId>
            <ArticleId IdType="pubmed">27103470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharshar T, Porcher R, Demeret S, Tranchant C, Gueguen A, Eymard B, Nadaj-Pakleza A, Spinazzi M, Grimaldi L, Birnbaum S, Friedman D, Clair B; MYACOR Study Group. Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial. JAMA Neurol. 2021;78(4):426–433. https://doi.org/10.1001/jamaneurol.2020.5407</Citation>
        </Reference>
        <Reference>
          <Citation>Pascuzzi RM, Coslett HB, Johns TR (1984) Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 15:291–298. https://doi.org/10.1002/ana.410150316</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410150316</ArticleId>
            <ArticleId IdType="pubmed">6721451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Utsugisawa K, Suzuki S, Nagane Y et al (2014) Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle Nerve 50:493–500. https://doi.org/10.1002/mus.24213</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.24213</ArticleId>
            <ArticleId IdType="pubmed">24536040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CY, Lam CL, Pang SY et al (2015) Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese. J Neuroimmunol 289:177–181. https://doi.org/10.1016/j.jneuroim.2015.10.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2015.10.018</ArticleId>
            <ArticleId IdType="pubmed">26616888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen D, Peng Y, Li Z et al (2020) Prognostic Analysis of Thymoma-associated myasthenia gravis (MG) in Chinese patients and its implication of MG management: experiences from a tertiary hospital. Neuropsychiatr Dis Treat 16:959–967. https://doi.org/10.2147/NDT.S243519</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/NDT.S243519</ArticleId>
            <ArticleId IdType="pubmed">32341644</ArticleId>
            <ArticleId IdType="pmc">7166054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imai T, Suzuki S, Tsuda E, Nagane Y, Murai H, Masuda M, Konno S, Suzuki Y, Nakane S, Fujihara K, Suzuki N, Utsugisawa K (2015) Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle Nerve 51(5):692–696. https://doi.org/10.1002/mus.24438</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.24438</ArticleId>
            <ArticleId IdType="pubmed">25155615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang CS, Hsu HS, Huang BS et al (2005) Factors influencing the outcome of transsternal thymectomy for myasthenia gravis. Acta Neurol Scand 112:108–114. https://doi.org/10.1111/j.1600-0404.2005.00424.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2005.00424.x</ArticleId>
            <ArticleId IdType="pubmed">16008537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Perrot M, Liu J, Bril V et al (2002) Prognostic significance of thymomas in patients with myasthenia gravis. Ann Thorac Surg 74:1658–1662. https://doi.org/10.1016/s0003-4975(02)04083-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0003-4975(02)04083-3</ArticleId>
            <ArticleId IdType="pubmed">12440626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsinzerling N, Lefvert AK, Matell G et al (2007) Myasthenia gravis: a long term follow-up study of Swedish patients with specific reference to thymic histology. J Neurol Neurosurg Psychiatry 78:1109–1112. https://doi.org/10.1136/jnnp.2006.109488</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2006.109488</ArticleId>
            <ArticleId IdType="pubmed">17353257</ArticleId>
            <ArticleId IdType="pmc">2117543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andersen JB, Gilhus NE, Sanders DB (2016) Factors affecting outcome in myasthenia gravis. Muscle Nerve 54:1041–1049. https://doi.org/10.1002/mus.25205</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.25205</ArticleId>
            <ArticleId IdType="pubmed">27251303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomschik M, Hilger E, Rath J et al (2020) Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology 95:e1426–e1436. https://doi.org/10.1212/WNL.0000000000010209</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000010209</ArticleId>
            <ArticleId IdType="pubmed">32641537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papatestas AE, Genkins G, Kornfeld P et al (1987) Effects of thymectomy in myasthenia gravis. Ann Surg 206:79–88. https://doi.org/10.1097/00000658-198707000-00013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000658-198707000-00013</ArticleId>
            <ArticleId IdType="pubmed">3606235</ArticleId>
            <ArticleId IdType="pmc">1492935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim H, Lim YM, Lee EJ et al (2018) Factors predicting remission in thymectomized patients with acetylcholine receptor antibody-positive myasthenia gravis. Muscle Nerve 58:796–800. https://doi.org/10.1002/mus.26300</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.26300</ArticleId>
            <ArticleId IdType="pubmed">30020542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaufman AJ, Palatt J, Sivak M et al (2016) Thymectomy for myasthenia gravis: complete stable remission and associated prognostic factors in over 1000 cases. Semin Thorac Cardiovasc Surg 28:561–568. https://doi.org/10.1053/j.semtcvs.2016.04.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.semtcvs.2016.04.002</ArticleId>
            <ArticleId IdType="pubmed">28043477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu S, Li F, Chen B et al (2015) Eight-year follow-up of patients with myasthenia gravis after thymectomy. Acta Neurol Scand 131:94–101. https://doi.org/10.1111/ane.12289</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ane.12289</ArticleId>
            <ArticleId IdType="pubmed">25170783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanai T, Uzawa A, Kawaguchi N et al (2019) Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis. J Neurol Sci 396:8–11. https://doi.org/10.1016/j.jns.2018.10.018</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2018.10.018</ArticleId>
            <ArticleId IdType="pubmed">30391823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki Y, Utsugisawa K, Suzuki S et al (2011) Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open 1:e000313. https://doi.org/10.1136/bmjopen-2011-000313</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2011-000313</ArticleId>
            <ArticleId IdType="pubmed">22184587</ArticleId>
            <ArticleId IdType="pmc">3244661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda M, Utsugisawa K, Suzuki S et al (2012) The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve 46(2):166–173. https://doi.org/10.1002/mus.23398</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.23398</ArticleId>
            <ArticleId IdType="pubmed">22806364</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
